[Importance of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia]
- PMID: 11214557
[Importance of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia]
Abstract
Objectives: To determine the importance of Mycoplasma pneumoniae and Chlamydia pneumoniae in community-acquired pneumonia (CAP) of children from different latitudes and to compare clinical outcome using azithromycin (AZM) versus either amoxicillin-clavulanate (A-C) or erythromycin estolate (EE).
Methods: Ambulatory patients with CAP were identified at either the Children's Medical Center of Dallas, Texas or the Hospital del Niño of Panama City, Panama. Children 6 months to 15 years of age were enrolled and randomized to receive either AZM for 5 days or a 10 day course of either A-C or EE, for those younger or older than 5 years of age, respectively. Mycoplasma pneumoniae and C. pneumoniae were identified by measuring acute and convalescent serum antibody titers and by performing nasopharyngeal (NP) and oropharyngeal (OP) swabs for culture and polymerase chain reaction (PCR) testing.
Results: Overall 335 patients (168 in Dallas and 167 in Panama) were evaluated from February 1996 through December 1997. Acute M. pneumoniae infection was detected in 12 (7%) patients each in Dallas and Panama. Acute C. pneumoniae infection was observed in 10 (6%) children at each site. Infection caused by these "atypical" microorganisms occurred more frequently in children older than 5 years of age (23% vs 9%, P = 0.001, RR 2.5, 95% CI 1.4-4.3). No distinctive pattern of clinical or radiologic abnormalities was seen in relation to etiology. Clinical cure was achieved in 43 of 44 children infected by these bacteria regardless of treatment assignment.
Conclusion: Mycoplasma pneumoniae and C. pneumoniae are common etiologic agents of CAP in older children from different latitudes. Children with CAP present with similar clinical and radiologic findings to those caused by other etiologic agents. Outcome was excellent for the three treatment regimens studied.
Similar articles
-
Etiology and treatment of community-acquired pneumonia in ambulatory children.Pediatr Infect Dis J. 1999 Feb;18(2):98-104. doi: 10.1097/00006454-199902000-00004. Pediatr Infect Dis J. 1999. PMID: 10048679 Clinical Trial.
-
Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.Pediatr Pulmonol. 2003 Feb;35(2):91-8. doi: 10.1002/ppul.10180. Pediatr Pulmonol. 2003. PMID: 12526069 Clinical Trial.
-
Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children.Pediatr Infect Dis J. 1998 Oct;17(10):865-71. doi: 10.1097/00006454-199810000-00004. Pediatr Infect Dis J. 1998. PMID: 9802626 Clinical Trial.
-
Chlamydia pneumoniae and Mycoplasma pneumoniae.Semin Respir Crit Care Med. 2005 Dec;26(6):617-24. doi: 10.1055/s-2005-925525. Semin Respir Crit Care Med. 2005. PMID: 16388430 Review.
-
Importance of atypical pathogens of community-acquired pneumonia.Clin Infect Dis. 2000 Aug;31 Suppl 2:S35-9. doi: 10.1086/314058. Clin Infect Dis. 2000. PMID: 10984326 Review.
Cited by
-
Detection of Mycoplasma pneumoniae in Mexican children with community-acquired pneumonia: experience in a tertiary care hospital.Infect Drug Resist. 2019 Apr 18;12:925-935. doi: 10.2147/IDR.S193076. eCollection 2019. Infect Drug Resist. 2019. PMID: 31118700 Free PMC article.
-
Etiology and the challenge of diagnostic testing of community-acquired pneumonia in children and adolescents.BMC Pediatr. 2022 Mar 31;22(1):169. doi: 10.1186/s12887-022-03235-z. BMC Pediatr. 2022. PMID: 35361166 Free PMC article.
-
Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children.Cochrane Database Syst Rev. 2015 Jan 8;1(1):CD004875. doi: 10.1002/14651858.CD004875.pub5. Cochrane Database Syst Rev. 2015. PMID: 25566754 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous